A phase III, randomized, multicenter, double-blind, parallel-group, placebo-controlled safety and efficacy study of Adderall XR [SLI-381] [extended release] with an open label extension, in the treatment of adolescents aged 13-17 with ADHD [attention-deficit hyperactivity disorder]

Trial Profile

A phase III, randomized, multicenter, double-blind, parallel-group, placebo-controlled safety and efficacy study of Adderall XR [SLI-381] [extended release] with an open label extension, in the treatment of adolescents aged 13-17 with ADHD [attention-deficit hyperactivity disorder]

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2007

At a glance

  • Drugs Mixed amfetamine salts (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 18 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top